By: Emmanuel Amoah
AstraZeneca has reaffirmed its commitment to bridging the gap in lung cancer care across Africa, coinciding with World Lung Cancer Day.
The company aims to enhance health outcomes for lung cancer patients through initiatives focused on prevention, early detection, and patient advocacy.
Lung cancer remains the leading cause of cancer mortality worldwide, with Africa facing significant challenges in diagnosis and treatment.
According to the Global Cancer Observatory 2020, the incidence of lung cancer varies across African regions, with South Africa having the highest rates.
AstraZeneca’s efforts include the “Connect to Care initiative,” which improves the diagnostic journey for lung cancer patients, and the Diagnostic Patient Navigation program, which supports patients from initial suspicion to confirmed diagnosis.
The company has also installed EGFR testing capabilities in Kenya and commenced molecular testing in Nigeria, marking significant advancements in oncology care.
Dr. Khomotso Mashilane, Medical Director at AstraZeneca, emphasized the importance of early detection and precise diagnosis in improving lung cancer outcomes. “We are committed to leveraging our expertise and resources to bring advanced diagnostic capabilities to more regions, ensuring patients receive timely and effective treatment,” he said.
AstraZeneca’s initiatives aim to address the fragmented cancer diagnostic landscape in Africa, streamline diagnosis and treatment pathways, and provide patients with access to advanced treatments.
By doing so, the company hopes to improve the grim statistics surrounding lung cancer in Africa, where over 90% of cases are diagnosed at a late stage.
